The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment
Must be 18 Years to 75 Years, both male and female.
BMI ≤40 kg/m2.
Meeting the American College of Rheumatology (ACR) 2015 criteria for the classification of gouty arthritis.
≥4 acute gout flares within 1 year prior to screening
Gout caused by radiotherapy/chemotherapy, organ transplantation, tumors, etc.
Evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis.
Presence of severe renal function impairment.
Intolerance of subcutaneous injection.